Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics (Q33987036)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Cortisol and cytokines in chronic and treatment-resistant patients with schizophrenia: association with psychopathology and response to antipsychotics (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

0 references

0 references

author name string

Xiang Yang Zhang

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Dong Feng Zhou

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Lian Yuan Cao

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Gui Ying Wu

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Yu Cun Shen

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

1 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Neuropsychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1532-1538

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

HPA axis and cytokines dysregulation in schizophrenia: potential implications for the antipsychotic treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Effects of repeated injections of interleukin 1beta or lipopolysaccharide on the HPA axis in the newborn rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Cytokines and neuro-immune-endocrine interactions: a role for the hypothalamic-pituitary-adrenal revolving axis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Increased prevalence of antibrain antibodies in the sera from schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Blunted cortisol response to a psychosocial stressor in schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Hypothalamic-pituitary-adrenal axis function in chronic schizophrenia: association with clinical features

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

The positive and negative syndrome scale (PANSS) for schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Cytokines and the brain: implications for clinical psychiatry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

The inflammatory response system in treatment-resistant schizophrenia: increased serum interleukin-6.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Interleukin-2 and interleukin-6 in schizophrenia and mania: Effects of neuroleptics and mood stabilizers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

In vivo immunomodulatory effects of clozapine in schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Effects of atypical antipsychotics on the inflammatory response system in schizophrenic patients resistant to treatment with typical neuroleptics.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Increased serum interleukin-8 and interleukin-10 in schizophrenic patients resistant to treatment with neuroleptics and the stimulatory effects of clozapine on serum leukemia inhibitory factor receptor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Psychoneuroendocrinology of schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Platelet serotonin, plasma cortisol, and dexamethasone suppression test in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Psychoneuroimmunology and the cytokine action in the CNS: implications for psychiatric disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Increased serum soluble interleukin-2 receptors in Caucasian and Korean schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

CSF IL-1 and IL-2 in medicated schizophrenic patients and normal volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Immunosuppressive effects of clozapine and haloperidol: enhanced production of the interleukin-1 receptor antagonist

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Role of the cytokines in the hypothalamic-pituitary-adrenal and gonadal axes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

IL-6 enhances plasma IL-1ra, IL-10, and cortisol in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Dexamethasone suppression test in schizophrenia: Relationship to symptomatology, ventricular enlargement, and outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Schizophrenia: A neural diathesis-stress model

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

The role of interleukin-6 in the activation of the hypothalamo-pituitary-adrenocortical axis and brain indoleamines by endotoxin and interleukin-1 beta

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

The incidence of abnormal dexamethasone suppression in schizophrenia: a review and a meta-analytic comparison with the incidence in normal controls

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Decreased production of interleukin-2 (IL-2), IL-2 secreting cells and CD4+ cells in medication-free patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis: recovery during an 8-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

21 January 2018

Dexamethasone suppression test in positive and negative schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Decreased in vitro production of interferon-gamma and interleukin-2 in whole blood of patients with schizophrenia during treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

A molecular basis for bidirectional communication between the immune and neuroendocrine systems

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Physiopharmacological interactions between stress hormones and central serotonergic systems

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Impaired mitogen (PHA) responsiveness and increased autoantibodies in Caucasian schizophrenic patients with the HLA B8/DR3 phenotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Serum interleukin-6 concentration in schizophrenia: elevation associated with duration of illness

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitogen-stimulated interleukin-2 production in never-medicated, first-episode schizophrenic patients. The influence of age at onset and negative symptoms

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Hypothalamic-pituitary-adrenal activity during chronic central administration of interleukin-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Ethnicity greatly influences cytokine gene polymorphism distribution

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Elevated CSF levels of interleukin-2 in neuroleptic-free schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

T-cells and psychopathology in schizophrenia: relationship to the outcome of neuroleptic therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

The effect of diagnosis and age on the DST: a metaanalytic approach

1 reference

https://api.crossref.org/works/10.1038%2FSJ.NPP.1300756

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.NPP.1300756

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33987036&oldid=2196089117"